Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02222818 · ClinicalTrials.gov registry record · NA
Cardiac Resynchronization Therapy Efficacy Enhancements
A NA study of Atrial Fibrillation, sponsored by Medtronic Cardiac Rhythm and Heart Failure.
- Completed
- Registry status
- NA
- Development phase
- 71
- Enrollment target
- 19
- Study locations
NCT02222818 is a NA study of Atrial Fibrillation that has completed, run by Medtronic Cardiac Rhythm and Heart Failure. The registered enrollment target is 71 participants, below the 2,997-participant average among 202 other Atrial Fibrillation trials with a reported enrollment target (98% lower). The trial reports 19 study locations across 10 states.
The verdict
NCT02222818, a NA study of Atrial Fibrillation, has completed, sponsored by Medtronic Cardiac Rhythm and Heart Failure.
- COMPLETED
- Registry status
- NA
- Development phase
- 71 participants
- Enrollment target
- 19
- Study locations
Study Summary
The purpose of this study is to demonstrate that the amount of effective CRT (Cardiac Resynchronization Therapy) pacing during AF (atrial fibrillation) when CAFRPlus (Conducted AF Response Plus) is applied is not inferior to the amount of effective CRT pacing during AF when CAFR (Conducted AF Response) is applied.
Conditions Studied
Interventions
- DEVICE Conducted AF Response (CAFR)
- DEVICE Conducted AF Response Plus (CAFRPlus)
Study Locations (19)
Other
- Magyar Honvédség Honvédkorház - Budapest
- Policlinico Universitario Agostino Gemelli - Roma
- Azienda Ospedaliera Bolognini Seriate - Ospedale Bolognini - Seriate
- Azienda Ospedaliera Cardinale Panico - Tricase
- Prince Sultan Cardiac Center - Riyadh
- Vychodoslovensky ustav srdcovych a cievnych chorob, a.s. - Košice
- Mediclinic Panorama - Cape Town
- Liverpool Heart and Chest Hospital NHS Foundation Trust - Liverpool
- he Newcastle upon Tyne Hospitals NHS Foundation Trust - Freeman Hospital - Newcastle upon Tyne
Minnesota
- North Memorial Heart and Vascular - Minneapolis
- CentraCare - Saint Cloud
Florida
- Cardiac Arrythmia Services - Boca Raton
Iowa
- Iowa Heart Center - West Des Moines
North Carolina
- North Carolina Heart and Vascular - Raleigh
Ohio
- Mount Carmel - Columbus
Oklahoma
- Oklahoma Heart - Oklahoma City
Pennsylvania
- Berks Cardiology - Reading
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 71 participants |
| Start Date | 2014-10 |
| Est. Completion | 2016-01 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02222818
The ClinicalTrials.gov registry entry for NCT02222818 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 71 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 2,997-participant average among 202 other Atrial Fibrillation trials with a reported enrollment target (98% lower). The listed sponsor is Medtronic Cardiac Rhythm and Heart Failure, which has 115 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Atrial Fibrillation appearing as the primary indexed condition, and to 2 interventions - of which Conducted AF Response (CAFR) is the first listed.
NCT02222818 reports 19 study locations spanning 10 distinct geographic areas - top geographies include Other, Minnesota, Florida.
Frequently Asked Questions
What is clinical trial NCT02222818 about?
NCT02222818 is a clinical study titled "Cardiac Resynchronization Therapy Efficacy Enhancements". The purpose of this study is to demonstrate that the amount of effective CRT (Cardiac Resynchronization Therapy) pacing during AF (atrial fibrillation) when CAFRPlus (Conducted AF Response Plus) is applied is not inferior to the amount of effective CRT pacing during AF when CAFR (Conducted AF Respon...
What is the current status of trial NCT02222818?
This trial is currently completed. It is a NA study. The enrollment target is 71 participants. The study started on 2014-10. Estimated completion is 2016-01.
What conditions does trial NCT02222818 study?
This clinical trial studies the following conditions: Atrial Fibrillation.
What interventions are being tested in trial NCT02222818?
The interventions under investigation include: Conducted AF Response (CAFR) (DEVICE), Conducted AF Response Plus (CAFRPlus) (DEVICE).
Who is sponsoring clinical trial NCT02222818?
This trial is sponsored by Medtronic Cardiac Rhythm and Heart Failure, which has 115 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02222818 being conducted?
This trial has 19 study locations across Florida, Iowa, Minnesota, North Carolina, Ohio. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Atrial Fibrillation
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Renal Denervation + PVI vs PVI Alone for Persistent AF
RECRUITING · NA
-
Pericardiotomy in Cardiac Surgery
RECRUITING · NA
-
CellFX® Nanosecond Pulsed Field Ablation (nsPFA)™ Cardiac Surgery Clamp System to Treat Atrial Fibrillation
RECRUITING · NA
-
The CONFORM Pivotal Trial
RECRUITING · NA
-
Vascular Closure With a Device Compared to Manual Compression After Atrial Fibrillation Ablation: The LockeT II Study
RECRUITING · NA
-
The Fourth Left Atrial Appendage Occlusion Study
RECRUITING · NA
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.